DK200301683A - DNA sequence encoding the polypeptide [Ia] hpG-CSF, plasmids containing the sequence, thereby transformed / transfected host cells ...... - Google Patents
DNA sequence encoding the polypeptide [Ia] hpG-CSF, plasmids containing the sequence, thereby transformed / transfected host cells ...... Download PDFInfo
- Publication number
- DK200301683A DK200301683A DK200301683A DKPA200301683A DK200301683A DK 200301683 A DK200301683 A DK 200301683A DK 200301683 A DK200301683 A DK 200301683A DK PA200301683 A DKPA200301683 A DK PA200301683A DK 200301683 A DK200301683 A DK 200301683A
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- dna sequence
- hpg
- csf
- transformed
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
PATENTKRAV 1. DNA-sekvens, der ved eksprimering i en pro-karyotisk eller eukaryotisk værtscelle koder for et polypeptidprodukt, der besidder i det mindste en del af den primære struktur og en eller flere af de biologiske egenskaber for naturligt forekommende pluri-potent granulocyt kolonistimulerende faktor (hpG-CSF), hvor DNA-sekvensen er kendetegnet ved at kode for [Ala1]hpG-CSF. 2. cDNA sekvens ifølge krav 1. 3. Genomisk DNA-sekvens ifølge krav 1. 4. DNA-sekvens ifølge krav 1, kendetegnet ved, at den er kovalent associeret med en påviselig markørsubstans, især en radioaktiv markør. 5. Enkeltstrenget DNA-sekvens ifølge krav 4. 6. Biologisk funktionelt plasmid eller viral DNA-vektor, kendetegnet ved, at det inkluderer en DNA-sekvens ifølge krav 1. 7. Prokaryotisk eller eukaryotisk værtscelle, kendetegnet ved, at den er transformeret eller transficeret med en DNA-sekvens ifølge krav 1 på en sådan måde, at værtscellen kan eksprimere po-lypeptidproduktet [Ala1] hpG-CSF. 8. Prokaryotisk eller eukaryotisk værtscelle, kendetegnet ved, at den er stabilt transformeret eller transficeret med en DNA-vektor ifølge krav 6. 9. Værtscelle ifølge krav 7 eller 8, k ende t g n e t ved, at værten er en pattedyrscelle. 10. Fremgangsmåde til fremstilling af polypep-tidet [Ala1] hpG-CSF, kendetegnet ved, at man under egnede næringsbetingelser dyrker prokaryo-tiske eller især eukaryotiske værtsceller, der er transformeret eller transficeret med en DNA-sekvens ifølge krav 1 på en sådan måde, at de kan eksprimere det nævnte polypeptid, og at man isolerer det ønskede polypeptid fra ekspressionen af DNA-sekvensen. 11. [Ala1]hpG-CSF som ikke naturligt forekommende polypeptid, kendetegnet ved, at det er produkt af ekspression i en prokaryotisk eller især eukaryotisk værtscelle af en DNA-sekvens ifølge krav 1. 12. Farmaceutisk præparat, kendetegnet ved, at det omfatter en effektiv mængde af po-lypeptidet ifølge krav 11 og/eller fremstillet ifølge krav 10, og et farmaceutisk acceptabelt fortyndingsmiddel, adjuvans eller bærer. 13. Farmaceutisk præparat ifølge krav 12, yderligere kendetegnet ved at være frit for association med noget som helst humant protein. 14. Anvendelse af polypeptidet ifølge krav 11 til fremstilling af et lægemiddel til tilvejebringelse af hæmatopoietisk terapi på et pattedyr.A DNA sequence which, upon expression in a prokaryotic or eukaryotic host cell, encodes a polypeptide product possessing at least part of the primary structure and one or more of the biological properties of naturally occurring pluripotent granulocyte colony stimulating factor (hpG-CSF), wherein the DNA sequence is characterized by encoding [Ala1] hpG-CSF. A cDNA sequence according to claim 1. A genomic DNA sequence according to claim 1. A DNA sequence according to claim 1, characterized in that it is covalently associated with a detectable marker substance, in particular a radioactive marker. A single-stranded DNA sequence according to claim 4. A biologically functional plasmid or viral DNA vector, characterized in that it includes a DNA sequence according to claim 1. 7. Prokaryotic or eukaryotic host cell, characterized in that it is transformed or transfected with a DNA sequence according to claim 1 in such a way that the host cell can express the polypeptide product [Ala1] hpG-CSF. A prokaryotic or eukaryotic host cell, characterized in that it is stably transformed or transfected with a DNA vector according to claim 6. A host cell according to claim 7 or 8, characterized in that the host is a mammalian cell. Process for producing the polypeptide [Ala1] hpG-CSF, characterized in that, under suitable nutritional conditions, prokaryotic or, in particular, eukaryotic host cells transformed or transfected with a DNA sequence according to claim 1 are cultured in such manner. , that they can express the said polypeptide and that the desired polypeptide is isolated from the expression of the DNA sequence. [Ala1] hpG-CSF as a non-naturally occurring polypeptide, characterized in that it is the product of expression in a prokaryotic or, in particular, eukaryotic host cell of a DNA sequence according to claim 1. 12. A pharmaceutical composition comprising an effective amount of the polypeptide of claim 11 and / or prepared according to claim 10, and a pharmaceutically acceptable diluent, adjuvant or carrier. Pharmaceutical composition according to claim 12, further characterized by being free from association with any human protein. Use of the polypeptide of claim 11 for the manufacture of a medicament for providing hematopoietic therapy to a mammal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200301683A DK175465B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76895985A | 1985-08-23 | 1985-08-23 | |
| US76895985 | 1985-08-23 | ||
| US83554886 | 1986-03-03 | ||
| US06/835,548 US4810643A (en) | 1985-08-23 | 1986-03-03 | Production of pluripotent granulocyte colony-stimulating factor |
| DK198702044A DK174980B1 (en) | 1985-08-23 | 1987-04-22 | Isolated polypeptide having properties such as hpG-CSF, DNA sequence encoding it, plasmids containing the sequence, transformed / transfected host cells, method for producing the polypeptide, pharmaceutical composition containing it ... |
| DK204487 | 1987-04-22 | ||
| DK200301683A DK175465B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301683 | 2003-11-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200301683A true DK200301683A (en) | 2003-11-12 |
| DK175465B1 DK175465B1 (en) | 2004-11-01 |
Family
ID=29715751
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200301683A DK175465B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301684A DK175466B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301685A DK175551B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200301684A DK175466B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301685A DK175551B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
Country Status (1)
| Country | Link |
|---|---|
| DK (3) | DK175465B1 (en) |
-
2003
- 2003-11-12 DK DK200301683A patent/DK175465B1/en not_active IP Right Cessation
- 2003-11-12 DK DK200301684A patent/DK175466B1/en not_active IP Right Cessation
- 2003-11-12 DK DK200301685A patent/DK175551B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK175465B1 (en) | 2004-11-01 |
| DK200301684A (en) | 2003-11-12 |
| DK175551B1 (en) | 2004-12-06 |
| DK200301685A (en) | 2003-11-12 |
| DK175466B1 (en) | 2004-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hapel et al. | Biologic properties of molecularly cloned and expressed murine interleukin-3 | |
| US5686278A (en) | Methods for enhanced retrovirus-mediated gene transfer | |
| CN111278972B (en) | Non-integrated DNA vectors for cytogenetic modification | |
| NO20032250L (en) | Use of a hpG-CSF polypeptide for the preparation of a drug for arresting the proliferation of leukemia cells | |
| DE69230882T2 (en) | CYTOSINDEAMINASE NEGATIVE SELECTION SYSTEM FOR COMMUNICATION AND THERAPIES | |
| TWI239352B (en) | Gene transfer method with the use of serum-free medium | |
| IL73111A (en) | Recombinant dna coding for polypeptides exhibiting multi-lineage cellular growth factor activity and/or mast cell growth factor activity,vector comprising them,transformed host cells and process for preparation of said polypeptides | |
| JPH06343477A (en) | Recombinant foamy virus vector for pharmaceutical and diagnostic use and preparation of recombinant foamy virus vector | |
| CN114107253B (en) | A system and method for gene editing using engineered cells | |
| DK200301683A (en) | DNA sequence encoding the polypeptide [Ia] hpG-CSF, plasmids containing the sequence, thereby transformed / transfected host cells ...... | |
| Schneider et al. | Targeted gene delivery into α9β1-integrin-displaying cells by a synthetic peptide | |
| Smith et al. | Genes transferred by retroviral vectors into normal and mutant myoblasts in primary cultures are expressed in myotubes | |
| US6485722B1 (en) | Method for selective engraftment of drug-resistant hematopoietic stem cells | |
| Garrido et al. | Protein truncation is not required for c-myb proto-oncogene activity in neuroretina cells | |
| Aints et al. | Enhanced ouabain resistance gene as a eukaryotic selection marker | |
| BR9708648B1 (en) | polypeptide, dna molecule, vector, process for polypeptide production, and pharmaceutical composition. | |
| Ng et al. | Cloning of a human DNA sequence that restores expression of hepatic functions in a dedifferentiated rat hepatoma cell | |
| Kametaka et al. | Reduction of CTLL‐2 cytotoxicity by induction of apoptosis with a Fas‐estrogen receptor chimera | |
| GEP19991639B (en) | DNA-Sequence, Cell, Vector, Polypeptide, Method for Obtaining and Pharmaceutical Formulation | |
| Pappas | Gene therapy biotechnology | |
| Merzak et al. | Transforming potential of truncated v-myb and stimulation of replication by gag-myb fusion products | |
| Sobol et al. | Gene Therapy | |
| du Sang et al. | Genetic manipulation of human red blood cells: progressing slowly but surely | |
| 目so | Induction of a carcinogenic oncornavirus in C57BL/6 mouse embryo cells by 5-iododeoxyuridine | |
| MXPA99003875A (en) | NOVEL flt-3 RECEPTOR AGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |